Logotype for MetaVia Inc

MetaVia (MTVA) investor relations material

MetaVia H.C. Wainwright 27th Annual Global Investment Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for MetaVia Inc
H.C. Wainwright 27th Annual Global Investment Conference summary5 Sep, 2025

Scientific rationale and program highlights

  • DA-1726 is a GLP-1/glucagon dual agonist with a unique 3:1 balance, aiming for superior glucose control and fat reduction in obesity patients compared to competitors with different ratios.

  • Phase 1 results for DA-1726 up to 32 mg showed strong glucose control and over 4% weight loss in four weeks, with a favorable safety profile.

  • DA-1241 is an oral GPR-119 agonist that increases natural GLP-1 production and has direct hepatic effects, showing compelling Phase 2A data in presumed NASH patients.

  • DA-1241 demonstrated an excellent safety profile in a 16-week Phase 2A trial, supporting further development and potential for combination therapies.

Differentiation, safety, and efficacy

  • DA-1726’s 3:1 GLP-1/glucagon ratio is designed to optimize both glucose control and fat loss, differentiating it from competitors like pemvidutide and retatrutide.

  • Early data indicate lower discontinuation rates due to adverse events compared to other dual agonists, with most GI side effects resolving after initial doses.

  • The ongoing 48 mg cohort in Phase 1 is testing higher efficacy and safety without titration, targeting at least 7% weight loss over eight weeks.

  • Advanced imaging and biomarker analysis (DEXA, FibroScan, HbA1c) are being used to assess fat loss, lean mass, and liver effects.

Strategic direction and partnerships

  • Plans include moving DA-1726 to Phase 2 with a focus on longer studies and broader patient populations, especially those with type 2 diabetes and NASH.

  • Active pursuit of partnerships or collaborations, particularly with large pharmaceutical companies seeking differentiated clinical-stage assets.

  • DA-1241’s development strategy centers on combination therapies, especially with FGF21 analogues and GLP-1s, to address the complex NASH landscape.

  • Ongoing discussions with companies closer to approval for ideal collaboration opportunities.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next MetaVia earnings date

Logotype for MetaVia Inc
Q3 20256 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next MetaVia earnings date

Logotype for MetaVia Inc
Q3 20256 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

MetaVia Inc is a U.S.-based biotechnology company focused on developing treatments for metabolic and rare genetic diseases. The company is engaged in the research and clinical development of novel therapeutics targeting underlying disease mechanisms, with a goal of addressing unmet medical needs. MetaVia utilizes proprietary technology platforms and collaborates with research institutions to advance its pipeline. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage